The novel PLN, which was conjugated to a specific aptamer sequence named the MAGE‐A3 aptamer (MAp), produces a non‐toxic nanoplatform that can effectively accumulate in lung cancer cells.[24] This DNA aptamer was identified against the tumor‐specific melanoma‐associated peptide antigen (MAGE‐A3111‐125).[25, 26] Based on the above description, the development of novel targeting methods is indispensable for tumor tracking. The gene discussed is MAGEA3; the disease is neoplasm.